C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 99 filers reported holding C4 THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,580,232 | -31.5% | 1,924,856 | +1.3% | 0.00% | – |
| Q2 2023 | $5,225,979 | -21.2% | 1,900,356 | -10.0% | 0.00% | – |
| Q1 2023 | $6,633,331 | -45.6% | 2,112,526 | +2.3% | 0.00% | – |
| Q4 2022 | $12,182,998 | -31.2% | 2,064,915 | +2.2% | 0.00% | -100.0% |
| Q3 2022 | $17,711,000 | +19.8% | 2,019,654 | +3.0% | 0.00% | – |
| Q2 2022 | $14,783,000 | -69.9% | 1,960,713 | -3.0% | 0.00% | -100.0% |
| Q1 2022 | $49,057,000 | -24.4% | 2,022,142 | +0.3% | 0.00% | 0.0% |
| Q4 2021 | $64,929,000 | -25.0% | 2,016,459 | +4.0% | 0.00% | -50.0% |
| Q3 2021 | $86,616,000 | +62.7% | 1,938,575 | +37.8% | 0.00% | +100.0% |
| Q2 2021 | $53,234,000 | +270.9% | 1,406,840 | +262.6% | 0.00% | – |
| Q1 2021 | $14,351,000 | -4.2% | 387,958 | -14.2% | 0.00% | – |
| Q4 2020 | $14,980,000 | – | 452,167 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |